Latest Breaking News On - Nnexon phase 1 - Page 1 : comparemela.com

Annexon Inc. (ANNX), a clinical-stage biopharmaceutical company focused on inflammatory-related diseases, reported Wednesday positive results from the Phase 1 trial of ANX1502, its oral small molecule inhibitor of the classical complement pathway.

More such health newsAnnexon incNnexon phase 1